(Reuters) – Johnson & Johnson’s coronavirus vaccine trial will resume very soon after investigators concluded a participant’s illness was unrelated to the vaccine, the Washington Post reported on Friday, citing two people familiar with the matter.
(Reporting by Munsif Vengattil; Editing by Anil D’Silva)
